新研究显示,在治疗EGFR突变的晚期肺癌方面,萨基图苏马布提鲁莫特干的效果优于多塞塔塞尔. New study shows sacituzumab tirumotecan outperforms docetaxel in treating advanced lung cancer with EGFR mutations.

《英国医学杂志》的一项新研究表明,在用EGFR突变治疗先进的非小细胞肺癌方面,sac-TMT在治疗高级非小细胞肺癌方面优于甲壳类。 A new study in The British Medical Journal shows that sacituzumab tirumotecan (sac-TMT) outperforms docetaxel in treating advanced non-small cell lung cancer with EGFR mutations. Sac-TMT改进了客观反应率、逐步无损生存和总体生存,减少了严重副作用。 Sac-TMT improved objective response rate, progression-free survival, and overall survival, with fewer severe side effects. 3月经国家医疗产品管理局批准,Sac-TMT是全球第一个被核准用于肺癌的TROP2 ADC。 Approved in March by the National Medical Products Administration, sac-TMT is the first TROP2 ADC approved globally for lung cancer. 这项研究以137名病人为基础,并在职业分类组织2025年年度会议上介绍。 The study was based on 137 patients and was presented at the 2025 ASCO Annual Meeting.